New Zealand - English - Medsafe (Medicines Safety Authority)

rex medical ltd - alendronate sodium trihydrate 91.37mg equivalent to 70 mg alendronate - tablet - 70 mg - active: alendronate sodium trihydrate 91.37mg equivalent to 70 mg alendronate excipient: magnesium stearate maize starch mannitol microcrystalline cellulose sodium starch glycolate

New Zealand - English - Medsafe (Medicines Safety Authority)

dr reddy's new zealand limited - alendronate sodium trihydrate 91.37mg equivalent to 70 mg alendronic acid - tablet - 70 mg - active: alendronate sodium trihydrate 91.37mg equivalent to 70 mg alendronic acid excipient: croscarmellose sodium magnesium stearate microcrystalline cellulose povidone purified water - alendronate 70 mg tablets are indicated in postmenopausal women for the treatment of osteoporosis to prevent fractures, including those of the hip and spine (vertebral compression fractures).

New Zealand - English - Medsafe (Medicines Safety Authority)

organon (new zealand) limited - alendronate sodium trihydrate 91.37mg equivalent to 70 mg alendronic acid - tablet - 70 mg - active: alendronate sodium trihydrate 91.37mg equivalent to 70 mg alendronic acid excipient: croscarmellose sodium lactose magnesium stearate microcrystalline cellulose - fosamax is indicated: · in postmenopausal women for the treatment of osteoporosis to prevent fractures, including those of the hip and spine (vertebral compression fractures). · in postmenopausal women who are at risk of developing osteoporosis fosamax is indicated for the prevention of osteoporosis to reduce the risk of future fracture. · for the treatment of osteoporosis in men to prevent fractures. · for the treatment and prevention of glucocorticoid-induced osteoporosis in men, premenopausal women and postmenopausal women receiving oestrogen. · for treatment of paget's disease of bone in men and women.

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - alendronate sodium trihydrate 91.37mg equivalent to alendronate 70mg; colecalciferol 140ug (5600 is vitamin d3);   - tablet - 70 mg/140 mcg - active: alendronate sodium trihydrate 91.37mg equivalent to alendronate 70mg colecalciferol 140ug (5600 is vitamin d3)   excipient: colloidal silicon dioxide magnesium stearate mannitol microcrystalline cellulose - indicated for the treatment of osteoporosis in select patients where vitamin d supplementation is recommended.

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - alendronate sodium trihydrate 91.37mg equivalent to alendronate 70mg; colecalciferol 70ug (2800 iu vitamin d3);   - tablet - 70 mg/70 mcg - active: alendronate sodium trihydrate 91.37mg equivalent to alendronate 70mg colecalciferol 70ug (2800 iu vitamin d3)   excipient: colloidal silicon dioxide magnesium stearate mannitol microcrystalline cellulose - indicated for the treatment of osteoporosis in select patients where vitamin d supplementation is recommended.

New Zealand - English - Medsafe (Medicines Safety Authority)

organon (new zealand) limited - alendronate sodium trihydrate 91.37mg equivalent to 70 mg alendronate anhydrous free acid; colecalciferol 140ug equivalent to 5600 iu;   - tablet - 70/140 - active: alendronate sodium trihydrate 91.37mg equivalent to 70 mg alendronate anhydrous free acid colecalciferol 140ug equivalent to 5600 iu   excipient: colloidal silicon dioxide croscarmellose sodium lactose magnesium stearate microcrystalline cellulose - fosamax plus is indicated for the treatment of osteoporosis in select patients where vitamin d supplementation is recommended.

New Zealand - English - Medsafe (Medicines Safety Authority)

organon (new zealand) limited - alendronate sodium trihydrate 91.37mg equivalent to to 70 mg anhydrous free acid; colecalciferol 70ug equivalent to 2800 iu;   - tablet - 70/70 - active: alendronate sodium trihydrate 91.37mg equivalent to to 70 mg anhydrous free acid colecalciferol 70ug equivalent to 2800 iu   excipient: colloidal silicon dioxide croscarmellose sodium lactose magnesium stearate microcrystalline cellulose - fosamax plus is indicated for the treatment of osteoporosis in select patients where vitamin d supplementation is recommended.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - alendronate sodium, quantity: 91.37 mg (equivalent: alendronic acid, qty 70 mg); colecalciferol, quantity: 0.07 mg - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; povidone; gelatin; croscarmellose sodium; medium chain triglycerides; microcrystalline cellulose; magnesium stearate; sucrose; butylated hydroxytoluene - tradenames are indicated for the treatment of: ? osteoporosis* in select patients where vitamin d supplementation is recommended,* prior to treatment, osteoporosis must be confirmed by: - the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults or by - the presence of osteoporotic fracture

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - alendronate sodium, quantity: 91.37 mg (equivalent: alendronic acid, qty 70 mg) - tablet - excipient ingredients: povidone; croscarmellose sodium; lactose monohydrate; magnesium stearate; microcrystalline cellulose - fonat is indicated for the treatment of: osteoporosis, including glucocorticoid-induced osteoporosis. fonat is indicated for the prevention of glucocorticoid-induced osteoporosis in those patients on long term corticosteroid therapy (see clinical trials, glucorticoid-induced osteoporosis). prior to treatment, osteoporosis must be confirmed by: - the finding of low bone mass of at least 2 standard deviations below the mean for young adults (gender specific), or by: - the presence of osteoporotic fracture.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - alendronate sodium trihydrate 91.37mg equivalent to 7 0mg alendronic acid - tablet - 70 mg - active: alendronate sodium trihydrate 91.37mg equivalent to 7 0mg alendronic acid excipient: croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose povidone - alendrate is indicated: · in postmenopausal women for the treatment of osteoporosis to prevent fractures, including those of the hip and spine (vertebral compression fractures). · in postmenopausal women who are at risk of developing osteoporosis alendrate is indicated for the prevention of osteoporosis to reduce the risk of future fracture. · for the treatment of osteoporosis in men to prevent fractures. · for the treatment and prevention of glucocorticoid-induced osteoporosis in men, premenopausal women and postmenopausal women receiving oestrogen. · for treatment of paget's disease of bone in men and women.